Satsuma Pharmaceuticals Inc (STSA) Stock Income Statement
USA - NASDAQ:STSA - US80405P1075 - Common Stock
1.1 USD
-0.01 (-0.9%)
1.07 USD
-0.03 (-2.73%)
| TTM (2023-3-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 54.44M | 59.22M | 51.17M | 48.33M | 28.88M | |||
| Research and Development | 39.99M | 44.09M | 37.63M | 36.27M | 24.20M | |||
| Selling, General, and Administrative Expenses | 14.45M | 15.13M | 13.53M | 12.06M | 4.69M | |||
| Operating Income | -54.44M | -59.22M | -51.17M | -48.33M | -28.88M | |||
| Interest Income/Expense | 1.34M | 892.00K | -6.00K | 770.00K | 710.00K | |||
| Other Income/Expense | null | null | null | 0 | 0 | |||
| Non Recurring Items | null | -11.73M | null | null | null | |||
| Income Before Taxes | -64.83M | -70.06M | -51.17M | -47.56M | -28.18M | |||
| Income Tax | null | null | null | null | null | |||
| Net Income | -64.83M | -70.06M | -51.17M | -47.56M | -28.18M | |||
| EBITDA | null | -58.71M | -50.77M | -48.09M | -28.74M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.99924 | -2.18751 | -1.754 | -2.73 | -1.62 | |||
| Non GAAP EPS | -2.01 | -2.19 | -1.77 | -2.74 | null | |||
| Statistics | ||||||||
All data in USD